Navigation Links
Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Date:5/25/2011

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor (TKI). Researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months.(1) The most common drug-related adverse events were rash and diarrhea, with three patients (11.5%) experiencing Grade 3 rash. Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  It is in late-stage development in advanced NSCLC and breast cancer.

Boehringer Ingelheim and QIAGEN are pleased that ASCO and the National Comprehensive Cancer Network (NCCN), two leading oncology organizations, recently recommended EGFR mutation testing for patients with metastatic or recurrent NSCLC.  These recommendations underscore the importance of genetic tumor testing to predict patient response to certain treatments, enabling personalized healthcare.  Boehringer Ingelheim has partnered with QIAGEN to develop a real-time polymerase chain reaction assay (real-time PCR) companion diagnostic test for afatinib that, if approved, could help physicians identify which patients may benefit from EGFR-targeted therapies.

"The ASCO and NCCN EGFR mutation testing recommendations reinforce the importance of identifying the appropriate NSCLC patients for clinical trials," said Christopher Corsico, M.D., M.P.H., Senior Vice President, Medicine and Regulatory, Boehringer Ingelheim Pharmaceuticals, Inc. "
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014   DaVita HealthCare Partners ... the nation,s largest and most innovative health care ... units, DaVita Clinical Research  (DCR) and  HealthCare Partners ... expand its extensive clinical research and data analytics ... (CKD) and end-stage renal disease (ESRD), as well ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... and development company, is pleased to announce the grant ... States relating to its GPCR-focused drug discovery ... significantly strengthens the global patent estate covering Heptares, technologies ... The suite of patents recently granted by the US ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and ... the addition of the "Drug Injection Devices ... http://photos.prnewswire.com/prnh/20130307/600769 ... of an expanding list of health conditions, drug ... that simplify the administration process and increase the ...
Breaking Medicine Technology:DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... March 31, 2012, on Thursday, May 10, 2012, following the ... an investor conference call and live webcast to discuss the ... Eastern Time / 2:00 p.m. Pacific Time on the same ...
... 2012 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI") ... today announced the signing of expanded strategic technology ... agreements, TDI now has the right to use ... Platform for their planned entry into the clinical ...
Cached Medicine Technology:Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 2Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 2Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 3Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 4Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 5Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDI's Planned Offering of Personalized Medicine Clinical Diagnostic Services 6
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Throughout her life, a woman may blame many things ... changes in her skin, hair and nails.// , ... the body increase and decrease, or if any abnormalities ... options which can address the changes that occur during ...
... Human cytomegalovirus, or CMV infects about 40,000 children before ... disabilities due to the virus – almost one an ... hearing loss, mental disability, a lack of coordination, and ... Prevention, CMV is as common a cause of serious ...
... an emergency life saving operation by writing a no good cheque ... Roy, 77, was warned that the long wait in the NHS ... was no way he could afford to pay for the ?6,500 ... a private hospital, knowing fully well that by the time it ...
... An Austrian company has just launched an alarm clock that promises ... face the day.// ,The aXbo Sleep Phase Alarm Clock checks ... your body is in a deep or light phase of sleep, ... International Trade Fair for Sports (ISPO) recently in Munich. ...
... Army immediately introduce yoga for its soldiers in field ... need for regular lectures and exercises on yoga techniques ... may be initiated in this direction," the standing committee ... and education in the defence sector" tabled in both ...
... hospital for sudden, worsening chest pain or a certain ... undergo early invasive treatment// rather than being treated conservatively, ... ,“Available evidence suggests that an early invasive strategy ... Michel Hoenig of the Centre for Research in Vascular ...
Cached Medicine News:Health News:A Balancing Act: Hormones and the Skin 2Health News:A Balancing Act: Hormones and the Skin 3Health News:A Balancing Act: Hormones and the Skin 4Health News:Creation of Cytomegalovirus Vaccine by an Innovative Method 2Health News:Wily Old Man Undergoes A life Saving Operation With A Worthless Cheque 2Health News:Yoga to De-stress Indian Army Soldiers 2Health News:Emergency Heart Patients Do Better With Invasive Approach 2Health News:Emergency Heart Patients Do Better With Invasive Approach 3Health News:Emergency Heart Patients Do Better With Invasive Approach 4
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
... Protection Goggles fit over ... used by the whole ... glass, 1.0 mm leaded ... increased scatter radiation protection. ...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Medicine Products: